Piśmiennictwo
[1] Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007;356(22):2301-2311.
[2] Stainsby D, MacLennan S, Hamilton PJ. Management of massive blood loss: a template guideline. Br J Anaesth 2000;85(3):487-491.
[3] Gutierrez G, Reines HD, Wulf-Gutierrez ME. Clinical review: hemorrhagic shock. Crit Care 2004;8(5):373-381.
[4] Hoyt DB, Bulger EM, Knudson MM, et al. Death in the operating room: an analysis of a multi-center experience. J Trauma 1994;37(3):426-432.
[5] Como JJ, Dutton RP, Scalea TM, et al. Blood transfusion rates in the care of acute trauma. Transfusion 2004;44(6):809-813.
[6] Spahn DR, Cerny V, Coats TJ, et al. Management of bleeding following major trauma: a European guideline. Crit Care 2007;11(1):R17.
[7] Johnson JW, Gracias VH, Schwab CW, et al. Evolution in damage control for exsanguinating penetrating abdominal injury. J Trauma 2001;51(2):261-269.
[8] Lynn M, Jeroukhimov I, Klein Y, et al. Updates in the management of severe coagulopathy in trauma patients. Intensive Care Med 2002;28(Suppl 2):S241-S247.
[9] Moore EE. Thomas G. Orr Memorial Lecture. Staged laparotomy for the hypothermia, acidosis, and coagulopathy syndrome. Am J Surg 1996;172(5):405-410.
[10] Rotondo MF, Schwab CW, McGonigal MD, et al. 'Damage control': an approach for improved survival in exsanguinating penetrating abdominal injury. J Trauma 1993;35(3):375-382.
[11] Brohi K, Cohen MJ, Ganter MT, et al. Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway? Ann Surg 2007;245(5):812-818.
[12] Rossaint R, Bouillon B, Cerny V, et al. Management of bleeding following major trauma: an updated European guideline. Crit Care 2010;14(2):R52.
[13] Paluszkiewicz P, Mayzner-Zawadzka E, Baranowski W, et al. Recommendations for the management of trauma or surgery-related massive blood loss. Pol Przegl Chir 2011;83(8):465-476.
[14] Johansson PI, Stensballe J, Rasmussen LS, et al. A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Ann Surg 2011;254(2):194-200.
[15] Ostrowski SR, Johansson PI. Endothelial glycocalyx degradation induces endogenous heparinization in patients with severe injury and early traumatic coagulopathy. J Trauma Acute Care Surg 2012;73(1):60-66.
[16] Ives C, Inaba K, Branco BC, et al. Hyperfibrinolysis elicited via thromboelastography predicts mortality in trauma. J Am Coll Surg 2012;215(4):496-502.
[17] Lacroix R, Gnat-George F. Microparticles: New Protagonists in Pericellular and Intravascular Proteolysis. Semin Thromb Hemost 2013 (ahead of print).
[18] Ortolano S, Spuch C. tPA in the Central Nervous System: Relations Between tPA and Cell Surface LRPs. Recent Pat Endocr Metab Immune Drug Discov 2012 (ahead of print).
[19] Sun HY, Szlam F, Levy JH, et al. Antifibrinolytic agents reduce tissue plasminogen activator-mediated neuronal toxicity in vitro. Acta Anaesthesiol Scand 2009;53(3):325-331.
[20] Brohi K, Singh J, Heron M, et al. Acute traumatic coagulopathy. J Trauma 2003;54(6):1127-1130.
[21] Annecke T, Geisenberger T, Kurzl R, et al. Algorithm-based coagulation management of catastrophic amniotic fluid embolism. Blood Coagul Fibrinolysis 2010;21(1):95-100.
[22] Hess JR, Brohi K, Dutton RP, et al. The coagulopathy of trauma: a review of mechanisms. J Trauma 2008;65(4):748-754.
[23] Ferro D, Celestini A, Violi F. Hyperfibrinolysis in liver disease. Clin Liver Dis 2009;13(1):21-31.
[24] Trzebicki J, Kosieradzki M, Flakiewicz E, et al. Detrimental effect of aprotinin ban on amount of blood loss during liver transplantation: single-center experience. Transplant Proc 2011;43(5):1725-1727.
[25] Goh KY, Tsoi WC, Feng CS, et al. Haemostatic changes during surgery for primary brain tumours. J Neurol Neurosurg Psychiatry 1997;63(3):334-338.
[26] Kuepper F, Dangas G, Mueller-Chorus A, et al. Fibrinolytic activity and bleeding after cardiac surgery with cardiopulmonary bypass and low-dose aprotinin therapy. Blood Coagul Fibrinolysis 2003;14(2):147-153.
[27] Shakur H, Roberts I, Piot P, et al. A promise to save 100,000 trauma patients. Lancet 2013;380(9859):2062-2063.
[28] Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010;376(9734):23-32.
[29] Gluud LL, Klingenberg SL, Langholz E. Tranexamic acid for upper gastrointestinal bleeding. Cochrane Database Syst Rev 2012;(1):CD006640.
[30] Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev 2000;(4):CD000249.
[31] Gurusamy KS, Pissanou T, Pikhart H, et al. Methods to decrease blood loss and transfusion requirements for liver transplantation. Cochrane Database Syst Rev 2011;(12):CD009052.
[32] Bolliger D, Gorlinger K, Tanaka KA. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. Anesthesiology 2010;113(5):1205-1219.
[33] Franchini M, Lippi G. Fibrinogen replacement therapy: a critical review of the literature. Blood Transfus 2012;10(1):23-27.
[34] Schlimp CJ, Cadamuro J, Solomon C, et al. The effect of fibrinogen concentrate and factor XIII on thromboelastometry in 33% diluted blood with albumin, gelatine, hydroxyethyl starch or saline in vitro. Blood Transfus 2012;10(1):1-9.
[35] Fenger-Eriksen C, Tonnesen E, Ingerslev J, et al. Mechanisms of hydroxyethyl starch-induced dilutional coagulopathy. J Thromb Haemost 2009;7(7):1099-1105.
[36] Inaba K, Karamanos E, Lustenberger T, et al. Impact of Fibrinogen Levels on Outcomes after Acute Injury in Patients Requiring a Massive Transfusion. J Am Coll Surg 2012 (ahead of print).
[37] Bolliger D, Szlam F, Molinaro RJ, et al. Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. Br J Anaesth 2009;102(6):793-799.
[38] Dempfle CE, Kalsch T, Elmas E, et al. Impact of fibrinogen concentration in severely ill patients on mechanical properties of whole blood clots. Blood Coagul Fibrinolysis 2008;19(8):765-770.
[39] Fenger-Eriksen C, Ingerslev J, Sorensen B. Fibrinogen concentrate – a potential universal hemostatic agent. Expert Opin Biol Ther 2009;9(10):1325-1333.
[40] Norda R, Tynell E, Akerblom O. Cumulative risks of early fresh frozen plasma, cryoprecipitate and platelet transfusion in Europe. J Trauma 2006;60(6 Suppl):S41-S45.
[41] Fries D, Martini WZ. Role of fibrinogen in trauma-induced coagulopathy. Br J Anaesth 2010;105(2):116-121.
[42] Richardson VR, Schroeder V, Grant PJ, et al. Complement C3 is a substrate for activated factor XIII that is cross-linked to fibrin during clot formation. Br J Haematol 2013;160(1):116-119.
[43] Richardson VR, Cordell P, Standeven KF, et al. Substrates of Factor XIII-A: roles in thrombosis and wound healing. Clin Sci (Lond) 2013;124(3):123-137.
[44] Kasahara K, Souri M, Kaneda M, et al. Impaired clot retraction in factor XIII A subunit-deficient mice. Blood 2010;115(6):1277-1279.
[45] Thomas WG. Double trouble for type 1 angiotensin receptors in atherosclerosis. N Engl J Med 2005;352(5):506-508.
[46] Rea CJ, Foley JH, Sorensen B. Factor XIII in the treatment of hemophilia A. N Engl J Med 2012;366(3):281-283.
[47] Alioglu B, Ozsoy MH, Tapci E, et al. Successful use of recombinant factor VIIa in a child with Schoenlein-Henoch purpura presenting with compartment syndrome and severe factor XIII deficiency. Blood Coagul Fibrinolysis 2013;24(1):102-105.
[48] Schreiber MA. The beginning of the end for damage control surgery. Br J Surg 2012;99 Suppl:110-11.
[49] Sorensen B, Fries D. Emerging treatment strategies for trauma-induced coagulopathy. Br J Surg 2012;99(Suppl):140-50.
[50] Ostrowski SR, Sorensen AM, Larsen CF, et al. Thrombelastography and biomarker profiles in acute coagulopathy of trauma: a prospective study. Scand J Trauma Resusc Emerg Med 2011;19:64.
[51] Fenger-Eriksen C, Jensen TM, Kristensen BS, et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo-controlled clinical trial. J Thromb Haemost 2009;7(5):795-802.
[52] Martini WZ, Cortez DS, Dubick MA, et al. Thrombelastography is better than PT, aPTT, and activated clotting time in detecting clinically relevant clotting abnormalities after hypothermia, hemorrhagic shock and resuscitation in pigs. J Trauma 2008;65(3):535-543.